PharmacoEconomics - Open

2017 - 2025

Current editor(s): Timothy Wrightson and Christopher Carswell

From Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().

Access Statistics for this journal.
Is something missing from the series or not right? See the RePEc data check for the archive and series.

Volume 9, issue 4, 2025

Using Generative Artificial Intelligence in Health Economics and Outcomes Research: A Primer on Techniques and Breakthroughs pp. 501-517

Tim Reason, Sven Klijn, Will Rawlinson, Emma Benbow, Julia Langham, Siguroli Teitsson, Kasper Johannesen and Bill Malcolm

Measuring the Socioeconomic Impact of Cancer: A Systematic Review and Standardized Assessment of Patient-Reported Outcomes (PRO) Instruments pp. 519-539

Phu Duy Pham, Jasper Ubels, Rachel Eckford and Michael Schlander

A Systematic Literature Review of the Economic and Healthcare Resource Utilization Burden of Relapsed/Refractory Follicular Lymphoma pp. 541-570

Bijal Shah, Mei Xue, Wesley Furnback, Erlene K. Seymour, Jin Kim, Po-Ya Chuang, Madeline Dec and Keri Yang

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan pp. 571-584

Hardik Goswami, Atsushi Tajima, Taizo Matsuki and Amy Puenpatom

Cost-Effectiveness of Ultrasound Renal Denervation for Resistant Hypertension in Belgium, France and The Netherlands pp. 585-595

Rod S. Taylor, Kaylie Metcalfe, Antoine Cremer, Sofie Brouwers, Joost Daemen, Sam Carter, Kieran Murphy, Marie-Claude Morice, Isabelle Durand-Zaleski, Linh Ngo, Michel Azizi and Ajay J. Kirtane

Indirect Treatment Comparisons in EUnetHTA Relative Effectiveness Assessments: Learnings and Recommendations for the Implementation of EU Joint Clinical Assessments pp. 597-609

Sophie Beekhuizen, Menglu Che, Loraine Monfort, Mahmoud Hashim, Ali Azough, Nicole Kubitz, Adrian Griffin and Martin Price

Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified? pp. 611-626

Waranya Rattanavipapong, Thunyarat Anothaisintawee, Wanrudee Isaranuwatchai, Duangrurdee Wattanasirichaigoon, Thipwimol Tim-Aroon, Khunton Wichajarn, Achara Sathienkijkanchai, Pimlak Charoenkwan, Kanya Suphapeetiporn, Chanchai Traivaree, Chulaluck Kuptanon and Yot Teerawattananon

Optimizing Diabetic Retinopathy Screening at Primary Health Centres in India: A Cost-Effectiveness Analysis pp. 627-638

Neha Purohit, Parul Chawla Gupta, Sandeep Buttan, Akashdeep Singh Chauhan, Ranjan Kumar Choudhury, Vishali Gupta, Atul Kotwal and Shankar Prinja

Effects of Generic Entry on Market Shares and Prices of Originator Drugs: Evidence from Chinese Pharmaceutical Market pp. 639-648

Weimiao Li, Xiaoyu Li, Yaoguang He, Luwen Shi and Jing Chen

Cost-Effectiveness of Using Conditional Economic Incentives to Improve Pre-exposure Prophylaxis Adherence Among Male Sex Workers pp. 649-659

Carlos Chivardi, Alejandro Zamudio-Sosa, Marta Wilson-Barthes, Fernando Alarid-Escudero, Monica Gandhi, Kenneth H. Mayer, Don Operario and Omar Galárraga

Healthcare Expenditure Trajectories in the Last 5 Years of Life: A Retrospective Cohort Study of Decedents with Advanced Cancer and End-Stage Organ Diseases pp. 661-670

Sheryl Hui-Xian Ng, Palvinder Kaur, Laurence Lean Chin Tan, Mervyn Yong Hwang Koh, Andy Hau Yan Ho, Allyn Hum and Woan Shin Tan

Cost–Benefit Analysis of the Enhancing Men’s Awareness of Testicular diseases (E-MAT) Feasibility Trial: A Virtual Reality Experience to Increase Testicular Knowledge and Self-Examination among Male Athletes pp. 671-682

Aileen Murphy, Ann Kirby, Federica Blasio, Megan McCarthy, Frances Shiely, Josephine Hegarty, Martin P. Davoren, Janas M. Harrington, Gillian W. Shorter, David Murphy, Billy O’Mahony, Eoghan Cooke, Michael J. Rovito, Steve Robertson, Serena FitzGerald, Alan O. Connor, Mícheál O. Riordan and Mohamad M. Saab

Patient Validation of Estimation of Health Utility Values in Alopecia Areata pp. 683-692

Caleb Dixon, Thomas Price, Elin Gruffydd, Andrew Lloyd and Ernest H. Law

Economic Evaluation of Patiromer in Patients with Concomitant Heart Failure and Chronic Kidney Disease in Italy pp. 693-706

M. Senni, E. Paoletti, Ewa Stawowczyk, M. Hale and A. Ramirez Arellano

Volume 9, issue 3, 2025

From Vision to Reality: The EU’s Pharmaceutical Reforms and the Path to Improved Access pp. 331-339

Caitlin Main, Cathrin Schäfer and Panos Kanavos

Do We Understand Unmet Need? A Proposal to Use Length-Of-Life Equivalent (LOLE) as a Patient-Centric Measure of Unmet Need pp. 341-350

Kevin Marsh, Robert F. Reynolds, Linda Nelsen, Stephen Watt, Omar A. Escontrías and Brett Hauber

Cost Effectiveness of Left Ventricular Assist Devices (LVADs) as Destination Therapy: A Systematic Review pp. 351-363

Tuba Saygın Avşar, Louise Jackson, Pelham Barton, Sophie Beese, Okeke Ogwulu Chidubem, Sern Lim, David Quinn, Malcolm J. Price and David J. Moore

Economic Burden of Acute Myeloid Leukemia in European Union: Results from a Systematic Review of Literature pp. 365-378

Alisha Saeed, Zermina Tasleem, Sohail Ayaz Muhammad, Anees Rehman, Shahid Shah, Qurratul Ain Jamil, Hajra Siddiqui, Hidayah Karuniawati and Saleh Karamah Al-Tamimi

Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults pp. 379-397

Andrew H. Briggs, François-Xavier Chalet, Jacie Cooper, Peter Graham, Stephen Palmer, Paul Miller, Andrew Walker, Berkeley Greenwood and Charles M. Morin

COVID-19 Vaccine Preferences in China: A Comparison of Discrete Choice Experiment and Profile Case Best–Worst Scaling pp. 399-413

Enxue Chang, Yanni Jia, Xiaoying Zhu, Lunan Wang, Ying Yan, Kejun Liu and Weidong Huang

Pricing for Multi-Indication Drugs in the Italian Regulatory Context pp. 415-422

Maria Grazia Ursino, Annalisa Milano, Filippo Viti Angelis, Eva Alessi and Francesco Trotta

Burden of Disease and Cost of Illness of Triple-Negative Breast Cancer in Portugal pp. 423-431

Joana Silva, Gabriela Sousa, Luís Costa, Margarida Brito, Sónia Oliveira, Bernardo Rodrigues, João Ferreira, Margarida Borges and Luís Miguel

Predicting Danish EQ-5D-5L Utilities Based on United Kingdom EQ-5D-3L Utilities for Use in Health Economic Models pp. 433-443

Einar B. Torkilseng, Nathan Clarke, Liza Sopina, Lars Oddershede, Rasmus Trap Wolf, Rachael Lawrance, Andrew Trigg, Bryan Bennett and James W. Shaw

Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database pp. 445-459

Pavo Marijic, Roman Kliemt, Martin Krammer, Nikolaus Kolb, Theo Last, Andreas Ambrosch, Santiago Ewig, Rembert Koczulla, Jörg Schelling, Claus Vogelmeier, Maria Waize, Manuela Stierl, Maria João Fonseca, Sara Pedron and Alen Marijam

So Many Choices, So Little Value: Potential Savings from Selecting Cost-Effective Proton Pump Inhibitors pp. 461-469

Hye-Young Kwon

Very Early Health Technology Assessment for Potential Predictive Biomarkers in the Treatment of Advanced Non-Small Cell Lung Cancer pp. 471-485

Leila-Sophie Otten, Alessandra I. G. Buma, Berber Piet, Rob Heine, Michel M. Heuvel and Valesca P. Retèl

Semaglutide 2.4 mg versus Liraglutide 3 mg for the Treatment of Obesity in Greece: A Short-Term Cost-Effectiveness Analysis pp. 487-497

Panagiotis Papantoniou and Nikolaos Maniadakis

Publisher Correction: Pricing for Multi-Indication Drugs in the Italian Regulatory Context pp. 499-499

Maria Grazia Ursino, Annalisa Milano, Filippo Viti Angelis, Eva Alessi and Francesco Trotta

Volume 9, issue 2, 2025

Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations pp. 161-178

Praveen Thokala, Henrique Duarte, Stuart Wright, Don Husereau, Isabelle Durand-Zaleski, Peter Lindgren, Roelien Postema, Gerardo Machnicki and Louis Garrison

Economic Burden of Haemophilia from a Societal Perspective: A Scoping Review pp. 179-205

Amr A. El-Sayed and Nancy S. Bolous

What Does Pharmaceutical 3D Printing Cost? A Framework and Case Study with Hydrocortisone for Adrenal Insufficiency pp. 207-215

Sejad Ayyoubi, Liesbeth Ruijgrok, Hugo Kuy, Renske Ham and Frederick Thielen

Economic Evaluation of Total Knee Replacement Compared with Non-Surgical Management for Knee Osteoarthritis in India pp. 217-229

Amatullah Sana Qadeer, Ananda Meher, Jennifer Rachel, Winnie Paulson, Abhilash Patra, Naline Gandhi, Nirupama Ay, Lipika Nanda, Sarit Kumar Rout and Ambarish Dutta

The Association between COVID-19 Status and Economic Costs in the Early Stages of the COVID-19 Pandemic: Evidence from a UK Symptom Surveillance Digital Survey pp. 231-245

Sung Wook Kim, Caterina Alacevich, Catia Nicodemo, Raphael Wittenberg, Simon Lusignan and Stavros Petrou

Cost-Effectiveness of Nivolumab Plus Ipilimumab versus Chemotherapy for Previously Untreated Metastatic NSCLC Using Mixture-Cure Survival Analysis Based on CheckMate 227 5-Year Data pp. 247-257

Alison D. Griffiths, Robert O. Young, Yong Yuan, Mohammad A. Chaudhary, Adam Lee, Jason Gordon and Philip McEwan

Health-Economic Modelling of Improved Behavior in Insulin Injection Technique in Belgium pp. 259-270

Kristof Theys, Sofie Vermander, Lieven Annemans, Christophe De Block, Michel P. Hermans, Imke Matthys, Frank Nobels, Trung Nguyen, Vanessa Preumont, Katerina Zakrzewska and Frank Vanderdonck

Comparing Different Implementation Strategies for Collaborative Dementia Care Management in Terms of Patients’ Characteristics, Unmet Needs, and the Impact on Quality of Life and Costs in Germany pp. 271-282

Moritz Platen, Wolfgang Hoffmann and Bernhard Michalowsky

Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis pp. 283-290

F. S. Mennini, A. Marcellusi, P. Sciattella, M. Scortichini, Angela Ragonese, F. Cattel, R. D’Antona, L. Mastro, S. Gori, G. Perrone, R. Migliorini and M. Trabucco Aurilio

Clinical Complications and Healthcare Resource Utilization Associated with Conventional Management of Sickle Cell Disease with Recurrent Vaso-occlusive Crises and Transfusion-Dependent β-Thalassemia in Germany pp. 291-300

Chuka Udeze, Nanxin Li, Colin Kunzweiler, Jessica Baldwin, Petra Tuzin, Sebastian Dietmar Zingel, Céline Vetter, Silvia Dombrowski, Elena Georgiadou-Schmidt, Aranzazu Alba and Roland Meisel

Cost-Utility Analysis of LifeVest® in Post-Myocardial Infarction Patients at Risk of Sudden Cardiac Death in England pp. 301-312

Vasileios Kontogiannis, Farai Goromonzi, Brigitte Both, Frank Semrau, Michael Branagan-Harris, Jowan Atkinson, Paul R. Roberts and Mehdi Javanbakht

From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment pp. 313-326

Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini and Emanuela Foglia

Correction: From Clinical to Non-clinical Outcomes in the Treatment of HIV: An Economic and Organizational Impact Assessment pp. 327-327

Lucrezia Ferrario, Barbara Menzaghi, Giuliano Rizzardini, Alessandro Roccia, Elisabetta Garagiola, Daniele Bellavia, Fabrizio Schettini and Emanuela Foglia

Correction: Mapping the World Health Organization Disability Assessment Schedule (WHODAS 2.0) onto SF-6D Using Swedish General Population Data pp. 329-329

Anna Philipson, Lars Hagberg, Liselotte Hermansson, Jan Karlsson, Emma Ohlsson-Nevo and Linda Ryen

Volume 9, issue 1, 2025

Costs of Illness for Huntington’s Disease: A Systematic Review pp. 5-13

Divya Patil, Emily F. Gorman and T. Joseph Mattingly

Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis pp. 15-25

Wendy I. Sligl, Charles Yan, Jeff Round, Xiaoming Wang, Justin Z. Chen, Cheyanne Boehm, Karen Fong, Katelynn Crick, Míriam Garrido Clua, Cassidy Codan, Tanis C. Dingle, Connie Prosser, Guanmin Chen, Alena Tse-Chang, Daniel Garros, David Zygun, Dawn Opgenorth, John M. Conly, Christopher J. Doig, Vincent I. Lau and Sean M. Bagshaw

Digital Versus Paper-Based Consent from the UK NHS Perspective: A Micro-costing Analysis pp. 27-39

Rachel Houten, Mohammad Iqbal Hussain, Antony P. Martin, Nick Ainsworth, Claudia Lameirinhas, Alexander W. Coombs, Simon Toh, Christopher Rao and Edward St John

Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study pp. 41-56

Aren Fischer, Stephen Mac, Erica Stivelman Freiman, John K. Marshall, Kim Rand and Juan M. Ramos-Goñi

Healthcare Resource Utilization and Associated Costs During the First 5 Years After Diagnosis and at the End of Life: A Nationwide Cohort Study of Patients with Multiple Myeloma in Finland pp. 57-68

Mikko Kosunen, Jarno Ruotsalainen, Alvar Kallio, Roope Metsä, Paavo Raittinen, Leena Lehmus, Maarit J. Korhonen and Timo Purmonen

Cost-Utility and Budget Impact Analysis of Adding SGLT-2 Inhibitors to Standard Treatment in Type 2 Diabetes Patients with Heart Failure: Utilizing National Database Insights from Thailand pp. 69-81

Tanawan Kongmalai, Juthamas Prawjaeng, Phorntida Hadnorntun, Pattara Leelahavarong, Usa Chaikledkaew, Ammarin Thakkinstian and Varalak Srinonprasert

Estimation of Health State Utility Values for Immunoglobulin A Nephropathy: A Time Trade-Off Analysis pp. 83-92

Zheng-Yi Zhou, Mark E. Bensink, Nisha C. Hazra, Chunyi Xu, Bruce Hendry, Claire C. Sharpe and Mo Zhou

Cost-Effectiveness of Fruquintinib for Refractory Metastatic Colorectal Cancer in the USA pp. 93-101

Dong-Won Kang, Patricio B. Lynn, Li Wang, Shouhao Zhou and Chan Shen

CMS’s Drug Price Negotiation Program 2023 Patient-Focused Listening Sessions: A Descriptive Analysis of Speaker Remarks pp. 103-113

Julie A. Patterson, Tyler D. Wagner, Rayan K. Salih, Gabri’el D. Shabazz and Jonathan D. Campbell

Mortality, Clinical Complications, and Healthcare Resource Utilization Associated with Managing Transfusion-Dependent β-Thalassemia and Sickle Cell Disease with Recurrent Vaso-occlusive Crises in Italy pp. 115-124

Chuka Udeze, Melania Dovizio, Chiara Veronesi, Luca Degli Esposti, Nanxin Li, Thi Xuan Mai Patricia Dang and Gian Luca Forni

Costs of Adverse Events in Patients with Advanced or Metastatic Renal Cell Carcinoma with First-Line Treatment pp. 125-136

Yan Chen, Ella X. Du, Manasvi Sundar, Keith A. Betts, Xin Yin, Samantha Eiffert, Karen Beauchamp, Andrew Delgado and Lisa Rosenblatt

Cost-Effectiveness of Three Different New-Generation Drug-Eluting Stents in the Randomised BIO-RESORT Trial at 3 Years pp. 137-145

Eline H. Ploumen, Martijn J. Oude Wolcherink, Rosaly A. Buiten, Tineke H. Pinxterhuis, Carine J. M. Doggen, Carl E. Schotborgh, Peter W. Danse, Martijn Scholte, K. Gert Houwelingen, Paolo Zocca, Xavier G. L. V. Pouwels and Clemens Birgelen

Integrating Multi-Cancer Early Detection (MCED) Tests with Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing pp. 147-160

Mussab Fagery, Hadi A. Khorshidi, Stephen Q. Wong, Özge Karanfil, Jon Emery and Maarten J. IJzerman